Zanaflex is often started at bedtime to minimise daytime drowsiness. If a morning dose is required for persistent spasticity, a low dose (2 mg) may be tried, but patients should assess how it affects alertness and discuss adjustments with their clinician.
Tizanidine is not a controlled substance and is not part of standard employment drug-screen panels. However, specific workplace testing policies should be reviewed.
Severe dizziness may indicate hypotension. Sit or lie down immediately, hydrate, and avoid sudden standing. If the symptom persists or worsens, contact a healthcare professional.
Rarely, patients report blurred vision or difficulty focusing, likely due to its central nervous system effects. Report any visual disturbances to a provider promptly.
Zanaflex is approved for spasticity, not for general musculoskeletal back pain. Off-label use for other pain conditions should only be considered under direct medical supervision.
Both are muscle relaxants, but tizanidine (Zanaflex) acts as an α₂-adrenergic agonist, whereas baclofen is a GABA-B receptor agonist. Their side-effect profiles and dosing schedules differ, influencing clinician choice.
Because Zanaflex can lower blood pressure, combining it with antihypertensives may increase the risk of hypotension. Blood pressure should be monitored, and dose adjustments may be necessary.
Typical excipients include lactose monohydrate, microcrystalline cellulose, and magnesium stearate. Patients with specific allergies should verify the exact formulation with the pharmacy.
Tizanidine is primarily metabolised in the liver; renal impairment alone usually does not require dose changes. However, severe renal dysfunction combined with hepatic issues warrants caution and possible dose reduction.
Concurrent use of multiple central muscle relaxants can intensify sedation and respiratory depression. Such combinations should only be prescribed after careful risk-benefit assessment.
Zanaflex is the brand name for the muscle-relaxant medication tizanidine. It is supplied as a pill in strengths of 2 mg and 4 mg. In Hong Kong, Zanaflex is a prescription-only product regulated by the Hong Kong Department of Health under the Pharmacy and Poisons Ordinance. Tizanidine belongs to the therapeutic class of pain-management agents, specifically acting as a central α₂-adrenergic agonist to reduce muscle tone.
Tizanidine binds to α₂-adrenergic receptors in the spinal cord and brain-stem. Activation of these receptors inhibits the release of excitatory neurotransmitters, which leads to a decrease in motor neuron firing. The result is reduced muscle spasticity and associated pain. Onset of action typically occurs within 1 hour, with peak effects at about 2 hours. The drug’s duration of action lasts roughly 6 hours, allowing twice-daily dosing for many patients. Tizanidine is metabolised primarily by the liver enzyme CYP1A2, and its metabolites are eliminated in the urine.
Zanaflex is approved in Hong Kong (and internationally) for the treatment of muscle spasticity caused by:
These indications are supported by the product label and regulatory evaluations. The medication is intended for adult patients who require reduction of abnormal muscle tone that interferes with daily activities.
Absolute contraindications
Known hypersensitivity to tizanidine or any tablet component
Severe hepatic impairment (Child-Pugh C)
Uncontrolled hypertension
Relative contraindications / cautions
Moderate hepatic impairment (Child-Pugh B) - dose reduction required
Concomitant use of potent CYP1A2 inhibitors (e.g., ciprofloxacin, fluvoxamine) - may need dose adjustment
Pregnancy (Category C) - only if benefits outweigh risks; discuss with a healthcare provider
Breastfeeding - tizanidine passes into breast milk; caution advised
Special populations such as elderly patients may be more sensitive to sedative effects and should start at the lowest dose.
These effects are usually mild and may improve with continued therapy.
If any of these occur, seek medical attention promptly.
Patients should provide a full medication list, including over-the-counter drugs and herbal supplements, to their prescriber.
Regular follow-up with a prescribing clinician ensures safe and effective use.
This article provides educational information about Zanaflex and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
